International meeting on influenza seroprevalence studiesArchived
Objective of meeting: To build consensus on best practices for influenza seroprevalence studies that will optimize the timing, quality, comparability and combinability of data
| Time | Agenda item | Speaker |
|
Wednesday February 9th, 2011, Day 1 |
||
| 8:00 - 8:30 | Registration | |
| 8:30 - 8:45 | Welcoming remarks | Patricia Huston, Public Health Agency of Canada, Ottawa, Ontario |
| 8:45 - 9:15 | Introduction of participants | All |
| 9:15 - 9:30 | Opening remarks from Canada’s Chief Public Health Officer | David Butler-Jones, Public Health Agency of Canada, Ottawa, Ontario |
| 9:30- 9:50 |
Objectives of Seroprevalence Studies: How can they inform public Health Action |
Angus Nicoll & Eeva Broberg, European Center for Disease Control, Stockholm, Sweden |
| 9:50- 10:20 |
Methodological Challenges With Influenza Seroprevelence Studies |
Katja Vandeemaele/John Tam/Tony Mounts, World Health Organization, Geneva, Switzerland (presentation via-teleconference) |
| 10:20- 10:45 | Refreshment break | |
| 10:45- 11:15 | Influenza Seroprevalence Laboratory Issues | Jacqueline Katz, Center for Disease Control and Prevention, Atlanta, United States |
| 11:15- 11:35 | Why Early Seroprevalence Studies are Critical for Modeling |
Steven Riley, Imperial College, London, England |
| 11:35- 11:55 | Early Serological Studies: Towards Best Practices |
Karen Laurie, World Health Organization Collaborating, Center Melbourne, Australia |
| 11:55- 12:10 |
Commentaries: A(H1N1) 2009 seroepidemiological surveys France - Daniel Levy Bruhl, France Baseline seroprevalence vs immunity - Ben Cowling, Hong Kong
|
Daniel Levy Bruhl, France Ben Cowling, Hong Kong |
| 12:10- 12:30 | Questions & discussions | |
| 12:30- 13:15 | Lunch | |
| 13:15- 13:35 |
Mid - late Serological Studies: Towards Best Practices |
Elizabeth Miller, Health Protection Agency, London, England |
| 13:35- 13:50 |
Issues in interpreting middle to late serological studies – sharing of experiences from cohort and cross-sectional studies of pdmH1N1 in Singapore |
Mark Chen, Singapore |
| 13:50- 14:10 |
Questions & discussions |
|
| 14:10- 14:30 |
Serological Studies at the Animal Animal-Human Interface: Laboratory Issues |
Jacqueline Katz, Center for Disease Control and Prevention, Atlanta, United States |
| 14:30- 15:00 | Refreshment break | |
| 15:00- 15:20 |
Immunity to influenza viruses |
Gustaaf Rimmelzwaan, Eramus University, Rotterdam, Netherlands |
| 15:20- 15:35 | Discussion | |
| 15:35- 16:00 |
Ethical Considerations in Seroprevalence Studies |
Don Willison, Ontario Agency for Health Protection and Promotion, Toronto, Ontario |
| 16:00- 16:30 |
Discussion/Day 1 Wrap up |
Patricia Huston, Public Health Agency of Canada, Ottawa, Ontario |
| Time | Agenda Item | Speaker |
| Thursday February 10th, 2011, Day 2 | ||
| 8:30- 9:00 | Registration | |
| 9:00- 9:10 | Welcome back | Patricia Huston, Public Health Agency of Canada, Ottawa, Ontario |
| 9:10- 9:30 |
Knowledge Transition Strategies to Promote Best Practices for Influenza Seroprevalence Studies |
Patricia Huston, Public Health Agency of Canada, Ottawa, Ontario |
|
9:30-11:30 |
Best Practices Recommendations: Group 1: Early StudiesGroup 2: Mid - late Studies |
Break Out SessionsGroup 1 (Quebec Room) - Karen LaurieGroup 2 (Laurier Room) – Elizabeth Miller |
| 11:30- 12:30 | Presentations of Best Practices: Early Studies |
Karen Laurie, World Health Organization Collaborating Center, Melbourne, Australia |
| 12:30- 13:30 | Lunch | |
| 13:30- 14:30 | Presentations of Best Practices: Mid - late Studies | Elizabeth Miller, Health Protection Agency, London, England |
| 14:30- 15:00 | Summary, Thank - you and Next Steps |
Patricia Huston, Public Health Agency of Canada, Ottawa, Ontario |
